Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01950312 · ClinicalTrials.gov registry record · Phase 2
The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease
A Phase 2 study of Autoimmune Inner Ear Disease, sponsored by Xoma (US).
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01950312: Completed Phase 2 study of Autoimmune Inner Ear Disease, sponsored by Xoma (US).
NCT01950312 is a Phase 2 study of Autoimmune Inner Ear Disease that has completed, run by Xoma (US). The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01950312, a Phase 2 study of Autoimmune Inner Ear Disease, has completed, sponsored by Xoma (US).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if gevokizumab therapy may be an alternate therapy in patients with steroid resistant Autoimmune Inner Ear Disease.
Conditions Studied
Interventions
- DRUG gevokizumab
Study Locations (1)
New York
- Long Island Jewish Medical Center, Hearing & Speech Center - New Hyde Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2013-08 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
What the finished NCT01950312 record still lists
NCT01950312 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Autoimmune Inner Ear Disease appearing as the primary indexed condition, and to 1 intervention - of which gevokizumab is the first listed.
NCT01950312 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01950312 about?
NCT01950312 is a clinical study titled "The Effects of Gevokizumab in Corticosteroid-resistant Subjects With Autoimmune Inner Ear Disease". The purpose of this study is to determine if gevokizumab therapy may be an alternate therapy in patients with steroid resistant Autoimmune Inner Ear Disease.
What is the current status of trial NCT01950312?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2013-08. Estimated completion is 2015-12.
What conditions does trial NCT01950312 study?
This clinical trial studies the following conditions: Autoimmune Inner Ear Disease.
What interventions are being tested in trial NCT01950312?
The interventions under investigation include: gevokizumab (DRUG).
Who is sponsoring clinical trial NCT01950312?
This trial is sponsored by Xoma (US), which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01950312 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autoimmune Inner Ear Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01950312's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia